A 73-gene lung cancer panel built for treatment guidance belongs in the clinic of the diagnosed patient rather than the wellness screen. Its purpose is to surface the genomic drivers of an individual tumor so that therapy, targeted agents, trial options, or sequencing decisions, can be matched to the molecular profile. Identifying which patient populations gain the most from such broad profiling is key to using the test well and avoiding unnecessary testing in low-yield settings.
Guideline bodies such as NCCN recommend broad molecular profiling for patients with advanced or metastatic non-small cell lung cancer, particularly adenocarcinoma and NSCLC not otherwise specified, because these groups are most likely to harbor a targetable driver. For these populations, a 73-gene panel can consolidate testing for EGFR, ALK, ROS1, BRAF, MET, RET, KRAS, NTRK, HER2, and other relevant alterations into one report, shortening the path to a matched therapy and reducing the number of separate assays a busy lab must run.
Single-marker testing forces a sequential, slow search; a wider panel examines many drivers at once, which matters when tissue is limited and time is short. Broad profiling also captures rarer alterations that still have defined or investigational targeted options, expanding trial eligibility. The population that benefits most is therefore any advanced NSCLC patient for whom a driver-directed strategy is plausible and for whom repeated biopsies would be impractical, including those being considered for first-line targeted or combination regimens.
Molecular profiles can change as disease evolves, so re-testing at progression, often via plasma cell-free DNA, is a recognized practice for patients who have exhausted an initial targeted option. A 73-gene panel supports this by providing a consistent reference framework across time points, helping clinicians track which alterations have emerged and whether a different targeted agent or a clinical trial is now the more appropriate next step.
Q: Who should receive a 73-gene lung cancer panel? A: Primarily patients with advanced or metastatic NSCLC, especially adenocarcinoma, where broad driver profiling guides therapy choice.
Q: Is this the same as a lung cancer risk test? A: No. This panel is for treatment guidance in diagnosed patients, not for estimating risk in healthy people.
Q: Why re-test the tumor later? A: Because resistance can introduce new alterations, re-testing at progression helps identify the next appropriate targeted option.
A 73-gene lung cancer panel built for treatment guidance belongs in the clinic of the diagnosed patient rather than the wellness screen. Its purpose is to surface the genomic drivers of an individual tumor so that therapy, targeted agents, trial options, or sequencing decisions, can be matched to the molecular profile. Identifying which patient populations gain the most from such broad profiling is key to using the test well and avoiding unnecessary testing in low-yield settings.
Guideline bodies such as NCCN recommend broad molecular profiling for patients with advanced or metastatic non-small cell lung cancer, particularly adenocarcinoma and NSCLC not otherwise specified, because these groups are most likely to harbor a targetable driver. For these populations, a 73-gene panel can consolidate testing for EGFR, ALK, ROS1, BRAF, MET, RET, KRAS, NTRK, HER2, and other relevant alterations into one report, shortening the path to a matched therapy and reducing the number of separate assays a busy lab must run.
Single-marker testing forces a sequential, slow search; a wider panel examines many drivers at once, which matters when tissue is limited and time is short. Broad profiling also captures rarer alterations that still have defined or investigational targeted options, expanding trial eligibility. The population that benefits most is therefore any advanced NSCLC patient for whom a driver-directed strategy is plausible and for whom repeated biopsies would be impractical, including those being considered for first-line targeted or combination regimens.
Molecular profiles can change as disease evolves, so re-testing at progression, often via plasma cell-free DNA, is a recognized practice for patients who have exhausted an initial targeted option. A 73-gene panel supports this by providing a consistent reference framework across time points, helping clinicians track which alterations have emerged and whether a different targeted agent or a clinical trial is now the more appropriate next step.
Q: Who should receive a 73-gene lung cancer panel? A: Primarily patients with advanced or metastatic NSCLC, especially adenocarcinoma, where broad driver profiling guides therapy choice.
Q: Is this the same as a lung cancer risk test? A: No. This panel is for treatment guidance in diagnosed patients, not for estimating risk in healthy people.
Q: Why re-test the tumor later? A: Because resistance can introduce new alterations, re-testing at progression helps identify the next appropriate targeted option.
english
français
Deutsch
Italiano
Русский
Español
português
Nederlandse
ελληνικά
日本語
한국
العربية
हिन्दी
Türkçe
indonesia
tiếng Việt
ไทย
বাংলা
فارسی
polski
